...
首页> 外文期刊>Expert Review of Molecular Diagnostics >Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer.
【24h】

Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer.

机译:鸟苷酸环化酶C:大肠癌患者分期和术后监测的分子标记。

获取原文
获取原文并翻译 | 示例

摘要

Staging patients with colorectal cancer defines their prognosis and therapeutic management. Unfortunately, histopathology, the current standard for staging, is relatively insensitive for detecting occult micrometastases and a significant fraction of patients are understaged and, consequently, undertreated. Similarly, current approaches to postoperative surveillance of patients with colorectal cancer detect disease recurrence at a point when interventions have little impact on survival. The detection of rare cells in tissue, for accurately staging patients, and in blood, for detecting disease recurrence, could be facilitated by employing sensitive and specific markers of disease. Guanylyl cyclase C (GCC), the receptor for the diarrheagenic bacterial heat-stable enterotoxin, is expressed selectively by cells derived from intestinal mucosa, including normal intestinal cells and colorectal tumor cells, but not by extragastrointestinal tissues and tumors. The nearly uniform expression of relatively high levels by metastatic colorectal tumors suggests that GCC may be a sensitive and specific molecular marker for metastatic colorectal cancer cells. Employing GCC reverse transcriptase PCR, occult colorectal cancer micrometastases were detected in lymph nodes that escaped detection by histopathology. Moreover, marker expression correlated with the risk of disease recurrence. Similarly, GCC reverse transcriptase PCR revealed the presence of tumor cells in blood of all patients examined with metastatic colorectal cancer and, in some studies, was associated with an increased risk of disease recurrence and mortality. These observations suggest that GCC reverse transcriptase PCR is a sensitive and specific technique for identifying tumor cells in extraintestinal sites and may be useful for staging and postoperative surveillance of patients with colorectal cancer.
机译:结直肠癌患者的分期定义了他们的预后和治疗管理。不幸的是,组织病理学是目前的分期标准,对于检测隐匿性微转移相对不敏感,并且很大一部分患者的病情进展缓慢,因此治疗不足。同样,目前对大肠癌患者进行术后监视的方法是在干预措施对生存率影响不大的时候检测到疾病复发。通过使用敏感的和特定的疾病标志物,可以促进组织中稀有细胞的检测,以准确地分期给患者;血液中的稀有细胞,以检测疾病的复发。腹泻性细菌热稳定肠毒素的受体鸟苷酰环化酶C(GCC)由肠粘膜来源的细胞(包括正常肠细胞和结直肠肿瘤细胞)选择性表达,而胃肠外组织和肿瘤则不表达。转移性结直肠肿瘤相对较高水平的近乎均匀表达表明,GCC可能是转移性结直肠癌细胞的敏感且特异性的分子标记。利用GCC逆转录酶PCR,在淋巴结中发现了隐匿的结直肠癌微转移,而这种淋巴结没有被组织病理学检测到。而且,标记物表达与疾病复发的风险相关。同样,GCC逆转录酶PCR显示所有接受过转移性结直肠癌检查的患者血液中都存在肿瘤细胞,在某些研究中,其与疾病复发和死亡的风险增加相关。这些观察结果表明,GCC逆转录酶PCR是鉴定肠外部位肿瘤细胞的灵敏且特异性的技术,可能对结直肠癌患者的分期和术后监测有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号